<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064438</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-D1</org_study_id>
    <nct_id>NCT03064438</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PROOF-OF CONCEPT STUDY OF THE SAFETY AND EFFICACY OF ACU-D1 OINTMENT IN SUBJECTS WITH ACNE ROSACEA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accuitis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accuitis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice&#xD;
      daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of&#xD;
      the participants received ACCU-D1 while one-third of the participants received vehicle&#xD;
      control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">June 18, 2018</completion_date>
  <primary_completion_date type="Actual">June 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Lesion Count at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Investigator's Global Assessment (IGA) Score at Weeks 2, 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.&#xD;
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema&#xD;
Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema&#xD;
Score 2 (mild): few papules and pustules present, no nodules, mild erythema&#xD;
Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema&#xD;
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Treatment Responders at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Treatment responders were defined as participants who have either (1) 2 ordinal or more reductions in the IGA score from baseline or (2) an IGA score of 0 or 1.&#xD;
The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.&#xD;
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema&#xD;
Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema&#xD;
Score 2 (mild): few papules and pustules present, no nodules, mild erythema&#xD;
Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema&#xD;
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Papule Lesions at Weeks 2, 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>Papule - raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pustule Lesions at Weeks 2, 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>Pustule - raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nodule Lesions at Weeks 2, 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Papules + Pustules Lesions at Weeks 2, 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>Papules + pustules lesions were the sum of counts of papule (raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material) and pustule (raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material) lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline to Week 14</time_frame>
    <description>Number of participants reporting any adverse event including local tolerability of signs and symptoms of irritation, clinical laboratory safety tests, and vital signs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present&#xD;
Score 1 (mild): slight erythema&#xD;
Score 2 (moderate): definite erythema&#xD;
Score 3 (severe): marked, fiery erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Day 1 (Post-application) and Weeks 2, 4, 8, and 14</measure>
    <time_frame>Day 1 (Post-application) and Weeks 2, 4, 8, and 14</time_frame>
    <description>Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present&#xD;
Score 1 (mild): slight erythema&#xD;
Score 2 (moderate): definite erythema&#xD;
Score 3 (severe): marked, fiery erythema</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acne Rosacea</condition>
  <arm_group>
    <arm_group_label>ACU-D1 Ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACU-D1 Ointment Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACCU-D1</intervention_name>
    <description>ACCU-D1</description>
    <arm_group_label>ACU-D1 Ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>ACU-D1 Ointment Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is male or non-pregnant and non-lactating female at least 18 years of age&#xD;
&#xD;
          -  Participant has a clinical diagnosis of stable papulopustular rosacea (type-2)&#xD;
&#xD;
          -  Participant has a total of ≥10 and ≤40 inflammatory lesions (papules, pustules, and&#xD;
             nodules) on the face&#xD;
&#xD;
          -  Participant has ≤2 nodules on the face&#xD;
&#xD;
          -  Participant has an investigator's global assessment (IGA) score of ≥3&#xD;
&#xD;
          -  If the participant is a woman of childbearing potential, she has a negative urine&#xD;
             pregnancy test and agrees to use an approved effective method of birth control for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Participant is in good general health and free of any known disease state or physical&#xD;
             condition which, in the investigator's opinion, might impair evaluation of rosacea or&#xD;
             which exposes the participant to an unacceptable risk by study participation&#xD;
&#xD;
          -  Participant is willing and able to follow all study instructions and to attend all&#xD;
             study visits&#xD;
&#xD;
          -  Participant is able to comprehend and willing to sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is pregnant, nursing, or planning to become pregnant during the duration&#xD;
             of the study&#xD;
&#xD;
          -  Participant has used systemic glucocorticosteroids within 42 days prior to Visit 1&#xD;
             (inhaled and ocular glucocorticosteroids are permitted)&#xD;
&#xD;
          -  Participant has used systemic antibiotics within 28 days prior to Visit 1&#xD;
&#xD;
          -  Participant has used any topical glucocorticosteroids on the face within 28 days prior&#xD;
             to Visit 1&#xD;
&#xD;
          -  Participant has used any prescription or over-the-counter product for the treatment of&#xD;
             acne or rosacea within 14 days prior to Visit 1&#xD;
&#xD;
          -  Participant is currently using any therapy that, in the investigator's opinion, is a&#xD;
             photosensitizer (for example, phenothiazines, amiodarone, quinine, thiazides,&#xD;
             sulphonamides, quinolones, etc.)&#xD;
&#xD;
          -  Participant currently has any skin disease (for example, psoriasis, atopic dermatitis,&#xD;
             eczema), or condition (for example, actinic keratosis, photo-damage, sunburn,&#xD;
             excessive hair, open wounds) that, in the investigator's opinion, might impair&#xD;
             evaluation of rosacea or which exposes the subject to an unacceptable risk by study&#xD;
             participation&#xD;
&#xD;
          -  Participant currently has, on the face, or has had on the face, any of the following&#xD;
             within the specified period prior to Visit 1 that, in the investigator's opinion,&#xD;
             might impair evaluation of rosacea or which exposes the subject to an unacceptable&#xD;
             risk by study participation:&#xD;
&#xD;
               -  A cutaneous malignancy; 180 days&#xD;
&#xD;
               -  Experienced a sunburn; 14 days&#xD;
&#xD;
          -  Participant has facial hair, that in the investigator's opinion, might impair&#xD;
             evaluation of rosacea or proper study medication application&#xD;
&#xD;
          -  Participant has a history of sensitivity to any of the ingredients in the study&#xD;
             medications&#xD;
&#xD;
          -  Participant has participated in an investigational drug trial in which administration&#xD;
             of an investigational study medication occurred within 30 days prior to Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <results_first_submitted>August 17, 2021</results_first_submitted>
  <results_first_submitted_qc>August 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03064438/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03064438/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at two sites in the United States.</recruitment_details>
      <pre_assignment_details>Eligible participants will be assigned in a random manner to 1 of the 2 study medications in a 2:1 ratio (ACU-D1 ointment: ACU-D1 ointment vehicle).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACU-D1 Ointment</title>
          <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>ACU-D1 Ointment Vehicle</title>
          <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified intention-to-treat (MITT) population included all randomized participants who were dispensed study medication and provided any post-baseline efficacy data.</population>
      <group_list>
        <group group_id="B1">
          <title>ACU-D1 Ointment</title>
          <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>ACU-D1 Ointment Vehicle</title>
          <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.59" spread="11.537"/>
                    <measurement group_id="B2" value="51.08" spread="12.473"/>
                    <measurement group_id="B3" value="50.08" spread="11.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total lesion count</title>
          <description>Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, &lt; 0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, &lt; 0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥ 0.5 cm in diameter.</description>
          <units>number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.00" spread="9.413"/>
                    <measurement group_id="B2" value="20.46" spread="9.777"/>
                    <measurement group_id="B3" value="18.80" spread="9.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythema score based on local tolerability as assessed by the investigator</title>
          <description>Erythema score at baseline (pre-application) was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present; Score 1 (mild): slight erythema; Score 2 (moderate): definite erythema; Score 3 (severe): marked, fiery erythema. The assessment was based on the safety population which included all randomized participants who received at least 1 dose of study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Lesion Count at Week 12</title>
        <description>Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Number of participants included participants in the MITT population with available data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lesion Count at Week 12</title>
          <description>Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter.</description>
          <population>Number of participants included participants in the MITT population with available data at Week 12.</population>
          <units>number of lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="1.08"/>
                    <measurement group_id="O2" value="-12.0" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of Least Squares (LS) Mean</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.162</ci_lower_limit>
            <ci_upper_limit>5.727</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Investigator's Global Assessment (IGA) Score at Weeks 2, 4, 8, and 12</title>
        <description>The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.&#xD;
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema&#xD;
Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema&#xD;
Score 2 (mild): few papules and pustules present, no nodules, mild erythema&#xD;
Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema&#xD;
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>MITT population. Number of participants analyzed included participants with available data at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Investigator's Global Assessment (IGA) Score at Weeks 2, 4, 8, and 12</title>
          <description>The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.&#xD;
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema&#xD;
Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema&#xD;
Score 2 (mild): few papules and pustules present, no nodules, mild erythema&#xD;
Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema&#xD;
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema</description>
          <population>MITT population. Number of participants analyzed included participants with available data at specific timepoint.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23" spread="0.2561"/>
                    <measurement group_id="O2" value="-29" spread="0.1653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="0.2387"/>
                    <measurement group_id="O2" value="-26" spread="0.2771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" spread="0.2538"/>
                    <measurement group_id="O2" value="-29" spread="0.2233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" spread="0.2588"/>
                    <measurement group_id="O2" value="-26" spread="0.3583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline at Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1099</p_value>
            <method>Van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline at Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1653</p_value>
            <method>Van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8437</p_value>
            <method>Van Elteren test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent change from baseline at Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4644</p_value>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Treatment Responders at Week 12</title>
        <description>Treatment responders were defined as participants who have either (1) 2 ordinal or more reductions in the IGA score from baseline or (2) an IGA score of 0 or 1.&#xD;
The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.&#xD;
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema&#xD;
Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema&#xD;
Score 2 (mild): few papules and pustules present, no nodules, mild erythema&#xD;
Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema&#xD;
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>MITT population. Number of participants analyzed included participants with available IGA score at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Treatment Responders at Week 12</title>
          <description>Treatment responders were defined as participants who have either (1) 2 ordinal or more reductions in the IGA score from baseline or (2) an IGA score of 0 or 1.&#xD;
The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.&#xD;
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema&#xD;
Score 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema&#xD;
Score 2 (mild): few papules and pustules present, no nodules, mild erythema&#xD;
Score 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema&#xD;
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema</description>
          <population>MITT population. Number of participants analyzed included participants with available IGA score at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Papule Lesions at Weeks 2, 4, 8, and 12</title>
        <description>Papule - raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Papule Lesions at Weeks 2, 4, 8, and 12</title>
          <description>Papule - raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material</description>
          <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
          <units>number of lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="1.09"/>
                    <measurement group_id="O2" value="-7.95" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="0.97"/>
                    <measurement group_id="O2" value="-8.22" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="1.16"/>
                    <measurement group_id="O2" value="-10.30" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="1.01"/>
                    <measurement group_id="O2" value="-10.98" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.495</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.571</ci_lower_limit>
            <ci_upper_limit>5.211</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.014</ci_lower_limit>
            <ci_upper_limit>2.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.965</ci_lower_limit>
            <ci_upper_limit>6.407</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.343</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.953</ci_lower_limit>
            <ci_upper_limit>5.469</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pustule Lesions at Weeks 2, 4, 8, and 12</title>
        <description>Pustule - raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pustule Lesions at Weeks 2, 4, 8, and 12</title>
          <description>Pustule - raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material</description>
          <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
          <units>number of lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.43"/>
                    <measurement group_id="O2" value="-0.98" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.20"/>
                    <measurement group_id="O2" value="-1.63" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.25"/>
                    <measurement group_id="O2" value="-1.29" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.31"/>
                    <measurement group_id="O2" value="-1.04" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.407</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.894</ci_lower_limit>
            <ci_upper_limit>2.155</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.291</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.342</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.734</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.763</ci_lower_limit>
            <ci_upper_limit>1.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in pustule lesions at Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.952</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.128</ci_lower_limit>
            <ci_upper_limit>1.197</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nodule Lesions at Weeks 2, 4, 8, and 12</title>
        <description>Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nodule Lesions at Weeks 2, 4, 8, and 12</title>
          <description>Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter</description>
          <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
          <units>number of lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.04"/>
                    <measurement group_id="O2" value="0.02" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.04"/>
                    <measurement group_id="O2" value="-0.05" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.04"/>
                    <measurement group_id="O2" value="-0.05" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.04"/>
                    <measurement group_id="O2" value="0.04" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.215</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.942</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.141</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in nodule lesions at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.284</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.067</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.542</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.198</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Papules + Pustules Lesions at Weeks 2, 4, 8, and 12</title>
        <description>Papules + pustules lesions were the sum of counts of papule (raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material) and pustule (raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material) lesions.</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Papules + Pustules Lesions at Weeks 2, 4, 8, and 12</title>
          <description>Papules + pustules lesions were the sum of counts of papule (raised inflammatory lesions, &lt;0.5 cm in diameter with no visible purulent material) and pustule (raised inflammatory lesions, &lt;0.5 cm in diameter with visible purulent material) lesions.</description>
          <population>MITT population. Number of participants analyzed included participants with available data at specified visits.</population>
          <units>number of lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="1.16"/>
                    <measurement group_id="O2" value="-8.97" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="1.06"/>
                    <measurement group_id="O2" value="-9.90" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="1.19"/>
                    <measurement group_id="O2" value="-11.65" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="1.08"/>
                    <measurement group_id="O2" value="-12.03" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.333</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.135</ci_lower_limit>
            <ci_upper_limit>6.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.591</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.882</ci_lower_limit>
            <ci_upper_limit>2.822</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.840</ci_lower_limit>
            <ci_upper_limit>6.758</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline at Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.131</ci_lower_limit>
            <ci_upper_limit>5.779</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants reporting any adverse event including local tolerability of signs and symptoms of irritation, clinical laboratory safety tests, and vital signs.</description>
        <time_frame>Baseline to Week 14</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants reporting any adverse event including local tolerability of signs and symptoms of irritation, clinical laboratory safety tests, and vital signs.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Week 12</title>
        <description>Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present&#xD;
Score 1 (mild): slight erythema&#xD;
Score 2 (moderate): definite erythema&#xD;
Score 3 (severe): marked, fiery erythema</description>
        <time_frame>Week 12</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication. Number of participants analyzed included participants with available data at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Week 12</title>
          <description>Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present&#xD;
Score 1 (mild): slight erythema&#xD;
Score 2 (moderate): definite erythema&#xD;
Score 3 (severe): marked, fiery erythema</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication. Number of participants analyzed included participants with available data at specified timepoints.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Day 1 (Post-application) and Weeks 2, 4, 8, and 14</title>
        <description>Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present&#xD;
Score 1 (mild): slight erythema&#xD;
Score 2 (moderate): definite erythema&#xD;
Score 3 (severe): marked, fiery erythema</description>
        <time_frame>Day 1 (Post-application) and Weeks 2, 4, 8, and 14</time_frame>
        <population>Safety population. Number of participants analyzed included participants with available data at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>ACU-D1 Ointment</title>
            <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACU-D1 Ointment Vehicle</title>
            <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Day 1 (Post-application) and Weeks 2, 4, 8, and 14</title>
          <description>Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.&#xD;
Score 0 (clear): no erythema present&#xD;
Score 1 (mild): slight erythema&#xD;
Score 2 (moderate): definite erythema&#xD;
Score 3 (severe): marked, fiery erythema</description>
          <population>Safety population. Number of participants analyzed included participants with available data at specified timepoints.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post-application)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Score 0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 1 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 2 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score 3 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 14</time_frame>
      <desc>Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>ACU-D1 Ointment</title>
          <description>Twice-daily application of ACU-D1 ointment to the face for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>ACU-D1 Ointment Vehicle</title>
          <description>Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Administration site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Application site perspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Science Officer</name_or_title>
      <organization>Accuitis, Inc.</organization>
      <phone>678-812-1492</phone>
      <email>info@accuitis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

